[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1982

Successful Pregnancy in a Patient With Dermatitis Herpetiformis Treated With Low-Dose Dapsone

Author Affiliations

San Francisco

Arch Dermatol. 1982;118(11):876. doi:10.1001/archderm.1982.01650230004004
Abstract

To the Editor.—  Dermatologists are increasingly using dapsone to treat a wide variety of serious cutaneous diseases. Inevitably, the problem of dapsone therapy in pregnancy will arise.Recently, a 33-year-old patient who had severe dermatitis herpetiformis requiring dapsone therapy became pregnant. Several telephone inquires disclosed a general lack of clinical experience with the use of sulfones in pregnancy. The disease was of 16 years' duration. The use of all other therapeutic modalities, including sulfapyridine, a glutenfree diet, adrenal steroids given for systemic effect, pyribenzamine, had either been unsuccessful or not tolerated. The patient required 25 to 50 mg/day of oral dapsone to control her disease reasonably well.The Physicians' Desk Reference statement was relatively ambiguous. Communications with the manufacturer, David P. Jacobus, MD, of Jacobus Pharmaceutical Co Inc, Princton, NJ, indicated a lack of experience with dapsone for the treatment of dermatitis herpetiformis during pregnancy. However, two articles on the

First Page Preview View Large
First page PDF preview
First page PDF preview
×